CIHR Internal Assessment - Report for the 2011 International Review - Long Descriptions
Figure 3: CIHR's budgets and partners
Figure 3A: Annual appropriations
2000–2001
2001–2002
2002–2003
2003–2004
2004–2005
2005–2006
2006–2007
2007–2008
2008–2009
2009–2010
2010–2011
Tri-Council and Earmarked
42.817
75.141
99.539
89.213
108.471
134.918
165.821
256.605
201.008
214.19
217.791
Base Budget
337.908
443.576
516.062
562.333
603.562
634.062
650.362
687.362
716.662
715.136
709.142
Administration
20.549
35.103
35.577
45.351
45.884
44.121
47.28
49.696
56.333
58.443
56.796
« Back to figure 3A
Figure 3B: Value contributed by partners
1999–2000
2000–2001
2001–2002
2002–2003
2003–2004
2004–2005
2005–2006
2006–2007
2007–2008
2008–2009
2009–2010
51.9
58.85248
61.30479
77.22007
76.62391
87.63498
107.3744
89.7003
157.4875
111.5871
118.169
« Back to figure 3B
Figure 3C: Number of partnership agreements in force
Academic
Charitable
International
Industry
Governments
2000–2001
12
29
5
3
16
2001–2002
22
60
8
6
28
2002–2003
30
108
12
11
51
2003–2004
34
145
14
12
74
2004–2005
32
182
20
20
74
2005–2006
47
198
25
26
91
2006–2007
36
205
25
33
92
2007–2008
71
201
30
35
109
2008–2009
71
193
32
30
113
2009–2010
47
195
32
28
112
« Back to figure 3C
Figure 4: Grants and awards expenditure
Figure 4A: Spend by program type
2000–2001
2001–2002
2002–2003
2003–2004
2004–2005
2005–2006
2006–2007
2007–2008
2008–2009
2009–2010
Operation
243.961496
325.151775
386.225372
438.809183
474.926413
518.191826
558.476979
598.884419
652.699090
647.051971
Equipment
9.518566
10.197071
10.165178
8.400805
9.285428
8.442181
4.132487
2.871645
1.834165
0.702566
RCTs
12.143052
20.458641
30.111634
27.615562
31.181794
28.691637
25.447905
34.395431
30.083550
31.371412
Salary
28.912628
35.039875
38.834716
39.363158
39.649918
36.186677
31.912278
30.702347
31.542238
29.839308
Training
31.830209
38.178189
39.796410
38.217338
39.582159
42.607358
46.254686
48.942226
51.547044
68.282383
Other
13.007395
19.505010
22.436575
23.176839
24.460345
23.626667
23.717321
23.425780
29.207870
30.998554
339.373346
448.530561
527.569885
575.582885
619.086057
657.746346
689.941656
739.221848
796.913957
808.246194
« Back to figure 4A
Figure 4B: Spend by theme
2000–2001
2001–2002
2002–2003
2003–2004
2004–2005
2005–2006
2006–2007
2007–2008
2008–2009
2009–2010
Social/ cultural/ environmental/ population health
9.2290674
24.69205
37.7738
47.52103
56.53312
59.56966
69.45206
84.37633
85.43178
90.54029
Health systems/services
4.9994597
16.00243
24.78004
32.12287
35.77505
36.21399
33.74661
41.90225
47.76797
55.5077
Clinical
27.217255
47.42268
64.05375
69.07362
76.72412
81.66097
85.33318
101.1742
109.8786
125.6834
Biomedical
160.1883
249.8036
312.3101
353.814
380.7431
419.358
438.7324
443.7841
474.4245
462.7377
Unspecified
137.73927
110.6098
88.65223
73.05134
69.31071
60.94368
62.67745
67.98496
79.41114
73.77714
« Back to figure 4B
Figure 4C: Spend on open and strategic competitions
1999–2000
2000–2001
2001–2002
2002–2003
2003–2004
2004–2005
2005–2006
2006–2007
2007–2008
2008–2009
2009–2010
Open
251.3513
304.603
375.481
414.261
425.567
447.921
469.804
479.9454
509.5328
533.6858
540.1099
Central strategic
23.85836
28.7715
55.962
60.086
66.854
74.61
82.984
101.7686
113.2742
126.6192
134.7351
Institute strategic
0
5.9995
17.088
53.223
83.161
96.555
104.958
108.228
116.415
136.609
133.401
Total
275.2096
339.374
448.531
527.57
575.582
619.086
657.746
689.942
739.222
796.914
808.246
% Strategic
8.67%
10.25%
16.29%
21.48%
26.06%
27.65%
28.57%
30.44%
31.07%
33.03%
33.18%
« Back to figure 4C
Figure 4D: Spend by institute affiliation, 2009-2010
$ Millions
Neurosciences, Mental Health and Addiction
$115
Infection and Immunity
$107
Circulatory and Respiratory Health
$82
Genetics
$80
Cancer Research
$79
Human Development, Child and Youth Health
$55
Nutrition, Metabolism and Diabetes
$51
Musculoskeletal Health and Arthritis
$42
Population and Public Health
$41
Health Services and Policy Research
$37
Aging
$31
Aboriginal Peoples' Health
$15
Gender and Health
$15
Primary institute not specified
$59
« Back to figure 4D
Figure 5: Canadian spending on health research 1998-2009
Figure 5A: Health R&D - funding sector
Federal government
Provincial governments
Business enterprise
Higher education
Private non-profit
Foreign
1998
382
172
940
864
244
352
1999
478
195
1,033
907
242
430
2000
560
218
1,157
1,000
284
477
2001
734
264
1,404
1,023
333
625
2002
958
297
1,589
1,283
389
757
2003
1,031
348
1,484
1,301
393
752
2004
1,093
353
1,641
1,606
458
918
2005
1,223
328
1,593
1,626
487
907
2006
1,176
332
1,520
1,668
508
738
2007
1,299
354
1,458
1,712
584
864
2008
1,325
359
1,469
1,734
593
869
2009
1,339
362
1,469
1,751
599
867
« Back to figure 5A
Figure 5B: Health R&D - performing sector
Federal government
Provincial governments
Business enterprise
Higher education
Private non-profit
1998
87
36
1,136
1,628
67
1999
103
31
1,280
1,823
48
2000
116
26
1,406
2,104
44
2001
152
29
1,768
2,383
51
2002
186
30
2,052
2,956
49
2003
196
29
1,939
3,087
58
2004
203
31
2,188
3,585
62
2005
210
26
2,100
3,767
61
2006
217
21
1,859
3,782
63
2007
258
29
1,885
4,014
85
2008
271
29
1,895
4,066
88
2009
274
29
1,888
4,106
90
« Back to figure 5B
Figure 6: Federal health research funding programs, 2009-2010
CIHR
NCEs
CECRs
CRC-CERC
IC
CFI
GC
CHSRF
Tri-Agency Funding
$808M
$29M
$27M
$165M
$140M
$450M
$120M
$18M
Federal Agencies
$450M
$18M
$120M
NCE : Networks of Centres of Excellence
CIHR : Canadian Institutes of Health Research
CRC : Canada Research Chairs
CECR : Centres of Excellence for Commercialization of Research
CERC : Canada Excellence Research Chairs
CFI : Canada Foundation for Innovation
GC : Genome Canada
CHSRF : Canadian Health Services Research Foundation
IC : Indirect Costs
« Back to figure 6
Figure 7: Increases in budget since 2000 (=1) for national health research funding agencies
MRC-UK
NIH-USA
NHMRC-Australia
CIHR
2000
1.00
1.00
1.00
1.00
2001
1.12
1.15
1.26
1.25
2002
1.16
1.31
1.55
1.67
2003
1.29
1.52
1.84
1.98
2004
1.19
1.56
2.02
2.18
2005
1.55
1.60
2.43
2.38
2006
1.70
1.60
2.66
2.56
2007
1.44
1.63
3.15
2.70
2008
2.17
1.64
3.69
3.13
2009
2.22
1.71
4.17
3.09
2010
2.39
1.74
4.22
3.14
« Back to figure 7
Figure 8: Annual value of operating grants (all programs), 2009-2010
Annual Value $K
Open Operating Grants
Other operating grants
< 20
122
148
20-39
355
172
40-59
328
171
60-79
441
124
80-99
471
138
100-119
699
226
120-139
672
22
140-159
428
30
160-179
169
9
180-199
74
5
200-219
38
3
220-239
12
3
240-259
11
4
260-279
17
5
280-299
9
1
300-349
11
7
350-399
5
3
>=400
8
30
« Back to figure 8
Figure 9: Applications to open operating grants competitions
Unsuccessful
Fundable but unsuccessful
Successful
Success rate
2000–2001
1,077
500
801
33.68%
2001–2002
1,104
604
833
32.72%
2002–2003
1,217
723
935
32.52%
2003–2004
1,284
915
880
28.58%
2004–2005
1,096
915
911
31.18%
2005–2006
1,241
1,167
957
28.44%
2006–2007
1,374
1,382
916
24.95%
2007–2008
1,322
1,743
829
21.29%
2008–2009
1,241
1,568
816
22.51%
2009–2010
1,284
1,599
797
21.66%
Total
12,240
11,142
8,649
« Back to figure 9
Figure 10A: Regional distribution of funding in 1999-2000 (MRC) and 2009-2010 (CIHR)
1999-2000
2009-2010
British Columbia
$25 million
$111 million
Prairie Provinces
$48 million
$104 million
Ontario
$114 million
$340 million
Quebec
$88 million
$232 million
Atlantic Provinces
$9 million
$30 million
« Back to figure 10A
Figure 10B: Number of research institutions 1999-2000 and 2009-2010
1999-2000
2009-2010
British Columbia
12
47
Prairie Provinces
14
33
Ontario
45
142
Quebec
48
91
Atlantic Provinces
7
19
« Back to figure 10B
Figure 11: PhDs awarded per million expenditures on R&D in the higher education sector
Canada
United Kingdom
United States
Germany
Italy
France
1999
0.9
2.15
1.55
3.00
0.65
1.86
2000
0.8
2.0
1.49
3.05
0.63
1.6
2001
0.75
2.2
1.42
2.82
0.63
1.55
2002
0.7
2.01
1.2
2.66
0.6
1.52
2003
0.6
2.1
1.18
2.5
0.72
1.25
2004
0.52
2.1
1.17
2.56
1.1
1.26
2005
0.54
2.02
1.30
2.85
1.65
1.48
2006
0.59
2.0
1.37
2.6
1.83
1.45
« Back to figure 11
Figure 12A: Growth in medicine publications
Canada
United Kingdom
United States
Germany
Japan
France
Italy
China
1999
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
2000
1.01
1.07
1.02
1.05
1.03
0.99
0.99
1.16
2001
1.04
1.04
1.04
1.12
0.96
0.98
1.03
1.23
2002
1.03
1.03
1.02
1.06
0.95
0.92
1.00
1.97
2003
1.22
1.10
1.10
1.16
0.98
1.01
1.12
2.80
2004
1.25
1.12
1.11
1.19
0.91
0.97
1.13
3.63
2005
1.45
1.21
1.25
1.26
0.97
1.05
1.26
5.31
2006
1.60
1.34
1.37
1.28
0.97
1.04
1.40
6.66
2007
1.72
1.38
1.40
1.18
0.96
1.10
1.42
7.28
2008
1.83
1.39
1.32
1.23
0.97
1.20
1.54
8.44
« Back to figure 12A
Figure 12B: Relative citations
Canada
United Kingdom
United States
Germany
Japan
France
Italy
China
1999
1.009899
0.807214
1
0.643556
0.521202
0.601912
0.648525
0.31772
2000
1.032176
0.797445
1
0.638523
0.510339
0.611577
0.686507
0.317246
2001
1.035665
0.810257
1
0.636887
0.55414
0.636887
0.69888
0.320855
2002
0.981072
0.822446
1
0.658234
0.522367
0.666867
0.726882
0.276395
2003
1.035326
0.85247
1
0.699812
0.554794
0.695834
0.754762
0.30113
2004
1.009659
0.868041
1
0.694002
0.577668
0.721624
0.780129
0.289203
2005
1.041361
0.894622
1
0.784891
0.588406
0.786503
0.879948
0.263323
2006
1.025349
0.861871
1
0.831827
0.612252
0.836756
0.848492
0.260063
2007
1.047173
0.907018
1
0.992788
0.652827
0.901365
0.937622
0.293177
2008
1.044479
0.959707
1
0.979069
0.614338
0.872318
0.903715
0.311879
« Back to figure 12B
Figure 13A: Growth in neuroscience publications
Canada
United Kingdom
United States
Germany
Japan
France
Italy
Spain
1999
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
2000
1.01
1.05
1.02
0.98
1.03
0.99
0.99
1.08
2001
0.97
1.11
0.98
0.90
0.97
0.90
1.03
1.04
2002
0.95
1.09
1.00
0.92
0.93
0.95
0.98
1.12
2003
1.05
1.15
1.08
0.94
0.98
0.99
1.00
1.13
2004
1.12
1.12
1.05
0.96
0.93
0.93
1.06
1.11
2005
1.19
1.24
1.14
1.06
0.93
0.97
1.14
1.30
2006
1.20
1.32
1.23
1.17
0.97
0.98
1.18
1.38
2007
1.29
1.33
1.23
1.08
0.98
0.98
1.21
1.39
2008
1.34
1.36
1.21
1.13
0.98
1.04
1.32
1.46
« Back to figure 13A
Figure 13B: Relative citations
Canada
United Kingdom
United States
Germany
Japan
France
Italy
Spain
1999
0.820784
0.902727
1
0.787163
0.530322
0.785562
0.690932
0.62369
2000
0.836132
0.97633
1
0.754653
0.521343
0.815345
0.705316
0.732855
2001
0.814732
0.984561
1
0.872152
0.541249
0.882509
0.694838
0.66918
2002
0.852448
0.962076
1
0.839745
0.542264
0.845898
0.701453
0.650766
2003
0.865336
1.019647
1
0.87631
0.555615
0.880983
0.765329
0.706068
2004
0.840335
0.970668
1
0.820561
0.577453
0.794593
0.78405
0.774122
2005
0.90269
1.050569
1
0.967276
0.599385
0.898323
0.834115
0.770715
2006
0.892868
1.040853
1
0.916512
0.606744
0.875039
0.77814
0.752016
2007
0.867937
0.941161
1
0.961249
0.653447
0.943494
0.913167
0.757128
2008
0.859979
1.048564
1
0.949663
0.643034
0.836228
0.831974
0.840128
« Back to figure 13B
Figure 14A: Growth in biochemistry, genetics and molecular biology publications
Canada
United Kingdom
United States
Germany
Japan
France
Italy
China
1999
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
2000
0.97
1.00
0.99
0.98
1.03
0.99
0.99
1.15
2001
0.98
0.97
0.99
0.94
0.97
0.90
1.03
1.17
2002
0.98
0.98
1.00
0.94
0.93
0.95
0.98
1.44
2003
1.13
1.11
1.08
1.06
0.98
0.99
1.00
2.13
2004
1.10
1.09
1.08
1.01
0.93
0.93
1.06
2.28
2005
1.22
1.14
1.14
1.13
0.93
0.97
1.14
2.86
2006
1.31
1.21
1.19
1.19
0.97
0.98
1.18
4.26
2007
1.42
1.24
1.21
1.21
0.98
0.98
1.21
4.77
2008
1.36
1.22
1.16
1.19
0.98
1.04
1.32
6.87
« Back to figure 14A
Figure 14B: Relative citations
Canada
United Kingdom
United States
Germany
Japan
France
Italy
China
1999
0.858127
0.88404
1
0.812369
0.543669
0.805332
0.708321
0.470208
2000
0.823852
0.876341
1
0.783895
0.52402
0.819531
0.708937
0.507905
2001
0.845578
0.874159
1
0.814784
0.54912
0.895343
0.704943
0.495965
2002
0.81701
0.91718
1
0.831908
0.55953
0.872831
0.723787
0.563301
2003
0.857624
0.924586
1
0.877104
0.562021
0.891141
0.774153
0.548987
2004
0.911874
0.942157
1
0.863874
0.589571
0.811267
0.800503
0.506346
2005
0.851625
0.952402
1
0.881716
0.608272
0.911642
0.846482
0.617628
2006
0.874951
0.924924
1
0.890123
0.612106
0.882772
0.785016
0.591695
2007
0.872166
0.955297
1
0.968234
0.645831
0.932496
0.902523
0.618676
2008
0.918306
0.988329
1
0.907302
0.604868
0.786596
0.782594
0.559853
« Back to figure 14B
Figure 15A: Growth in immunology and microbiology publications
Canada
United Kingdom
United States
Germany
Japan
France
Italy
Spain
1999
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
2000
0.93
0.96
0.99
0.90
1.01
0.89
1.02
1.03
2001
0.86
0.89
0.95
0.92
0.98
0.87
0.95
0.95
2002
0.89
0.88
0.93
0.88
0.97
0.83
0.96
1.05
2003
1.08
0.98
1.07
1.00
1.08
0.98
1.14
1.11
2004
1.07
0.96
1.08
1.00
1.01
0.89
1.10
1.18
2005
1.22
0.99
1.17
1.07
1.06
0.98
1.16
1.21
2006
1.32
1.07
1.20
1.10
1.06
1.00
1.15
1.37
2007
1.45
1.10
1.25
1.15
1.13
1.03
1.27
1.40
2008
1.39
1.04
1.16
1.14
1.06
1.02
1.33
1.49
« Back to figure 15A
Figure 15B: Relative citations
Canada
United Kingdom
United States
Germany
Japan
France
Italy
Spain
1999
0.866674
0.802001
1
0.862066
0.708482
0.748862
0.677046
0.679199
2000
0.885507
0.803255
1
0.913404
0.665999
0.83417
0.68298
0.58637
2001
0.745693
0.781226
1
0.841443
0.629573
0.730623
0.706647
0.615057
2002
0.782573
0.781558
1
0.843912
0.629735
0.745946
0.678785
0.581023
2003
0.871055
0.878055
1
0.890818
0.695274
0.805848
0.707186
0.690246
2004
0.902493
0.883073
1
0.926204
0.709286
0.821651
0.700976
0.661187
2005
0.868412
0.908936
1
0.898236
0.687649
0.830734
0.758338
0.698976
2006
0.909427
0.869144
1
0.909016
0.682337
0.822135
0.763229
0.70859
2007
0.867057
0.883542
1
0.937915
0.656208
0.900558
0.818266
0.747673
2008
0.885645
0.96837
1
0.947515
0.642336
0.915537
0.811262
0.832464
« Back to figure 15B
Figure 16: Growth of Canadian publications in selected areas relevant to its expanded mandate
Publications/yr
Medical Ethics
Health Policy & Services
Social Sciences, Biomedical
Nursing
1998
10
265
110
123
1999
7
155
95
136
2000
12
250
146
126
2001
16
273
102
153
2002
14
275
93
149
2003
23
278
255
154
2004
49
195
175
160
2005
52
607
221
253
2006
40
275
184
353
2007
59
458
318
351
2008
72
783
271
348
2009
84
1026
278
441
3yr moving averages
Medical Ethics
Health Policy & Services
Social Sciences, Biomedical
Nursing
1999
9.7
223.3
117.0
128.3
2000
11.7
226.0
114.3
138.3
2001
14.0
266.0
113.7
142.7
2002
17.7
275.3
150.0
152.0
2003
28.7
249.3
174.3
154.3
2004
41.3
360.0
217.0
189.0
2005
47.0
359.0
193.3
255.3
2006
50.3
446.7
241.0
319.0
2007
57.0
505.3
257.7
350.7
2008
71.7
755.7
289.0
380.0
« Back to figure 16
Figure 17: U.S. patents related to health awarded to Canadian inventors
Year
All Health Patents
CIHR-supported
non-CIHR
2002
126
90
36
2003
113
71
42
2004
104
76
28
2005
79
58
21
2006
89
68
21
2007
84
61
23
« Back to figure 17
Figure 18: Foreign collaboration - percentage of papers from each country with co-authors from another country
Year
Canada
United Kingdom
United States
Germany
Japan
Italy
France
China
1996
30.319
21.205
17.789
31.179
14.373
20.217
18.03
25.855
1997
29.152
19.93
16.037
29.187
13.983
20.289
17.671
24.559
1998
28.573
19.613
15.962
29.793
13.842
20.703
18.272
26.422
1999
25.762
18.339
14.68
21.077
11.562
18.036
16.103
23.024
2000
25.729
18.282
14.667
18.345
11.51
16.995
16.013
20.949
2001
24.291
17.612
14.117
16.087
10.491
16.705
15.207
16.961
2002
25.934
18.805
14.518
17.722
9.581
17.932
17.469
13.439
2003
36.069
27.325
19.241
24.931
13.877
25.403
24.086
16.423
2004
41.811
31.609
24.518
35.097
19.509
29.733
27.936
16.323
2005
41.654
32.796
24.673
37.408
19.592
30.991
29.198
14.027
2006
40.488
31.879
23.731
37.037
20.815
29.797
32.146
13.891
2007
42.672
34.125
25.109
41.508
23.501
32.02
33.312
15.525
2008
44.284
37.029
26.344
43.182
22.899
32.681
32.179
16.98
« Back to figure 18
Figure 19: CIHR spending on commercialization programs
2001-2002
2002–2003
2003–2004
2004–2005
2005–2006
2006–2007
2007–2008
2008–2009
2009–2010
Proof of Principal
4.330097
3.423588
3.537031
3.060467
4.810413
5.958022
6.650497
4.427559
1.809033
IP Management
2.000000
1.774500
1.288750
1.218040
2.437610
2.763336
3.503912
2.673728
1.749041
Science to Business
0.534000
0.345585
0.485964
0.005000
0.485529
NSERC-CIHR Initiative
0.960364
2.071651
3.038386
3.073925
4.294276
5.849815
CECR
73.512350
4.442000
4.442000
Business-led NCE
4.294276
5.898150
Industry-partnered
2.498812
4.565932
5.556881
4.392579
3.702909
4.419813
4.655228
4.932114
4.552753
Other
0.000000
0.000000
0.090750
2.069913
2.384494
0.913513
0.000000
0.000000
0.067374
« Back to figure 19
Figure 20A: Venture capital investments in the life sciences in Canada
$M
2001
$641
2002
$462
2003
$441
2004
$467
2005
$447
2006
$493
2007
$633
2008
$359
2009
$215
« Back to figure 20A
Figure 20B: R&D to sales ratio, Canada and seven comparator countries
R&D as % of sales
2000
2006
Switzerland
102.5%
105.0%
UK
35.1%
39.8%
Sweden
44.4%
30.7%
Germany
17.3%
22.1%
US
18.4%
19.4%
France
16.8%
16.4%
Canada
10.1%
8.1%
Italy
6.2%
6.8%
« Back to figure 20B
Figure 21: Number and value of ethics grants
grants open$
grants strategic$
open#
strategic #
2000-2001
0.09
0.29
2
3
2001-2002
0.20
0.29
7
7
2002-2003
0.40
0.37
9
10
2003-2004
0.39
1.36
7
21
2004-2005
0.60
2.49
11
29
2005-2006
0.96
2.83
15
36
2006-2007
1.24
2.83
17
41
2007-2008
1.47
4.20
16
49
2008-2009
1.01
4.60
12
74
2009-2010
1.02
5.03
13
62
« Back to figure 21
Figure 22: CIHR's Roadmap strategic plan
Invest in World-Class Research
Train, retain and sustain outstanding health researchers
Select and sustain research excellence
Promote interdisciplinary and international innovation
Address Health and Health System Research Priorities
Improve focus, coherence and impact from CIHR's strategic investments
Build strategies and initiatives that address health and health system priorities
Accelerate the Capture of Health and Economic Benefits of Health Research
Reap the socioeconomic benefits from research through KT and partnerships
Enhance the application of research and its evaluation
Achieve Organizational Excellence, Foster Ethics and Demonstrate Impact
Advance organizational excellence and ensure transparency and accountability
Evaluate the overall success of CIHR
Foster a culture of ethical research by promoting and assisting the discussion and application of ethical principles to health research
Assess progress and impact by demonstrating the impacts of CIHR investments
« Back to figure 22
Figure 23: Inter-relationship of proposed reforms to achieve CIHR's strategic direction
Top Down Strategy – Strategic Reform
Targeted to specified areas of health research and knowledge translation. These programs and initiatives are intended to:
Focus on gaps in specific research areas and research communities or
Leverage existing strengths for impact
Bottom Up Strategy – Reform of open suite of programs
Open to all areas of health research and knowledge translation. This suite of programs is intended to:
Capture excellence across all themes
Capture innovative/breakthrough research
Improve sustainability of long-term research enterprise
Integrate new talent
« Back to figure 23
Figure 24: Current enabling strategies
Patient-oriented Research
Global Health
International Collaboration
Northern
Strategic topics currently developing business plans
Enhance patient-oriented care and improve clinical results through scientific and technological innovations
Clinical trials networks
Personalized medicine
Support a high-quality, accessible and sustainable health care system
Community-based primary health care
Evidence-based decision support
Promote health and reduce the burden of chronic disease and mental illness, Alzheimer's and related dementias
Alzheimer's disease
Inflammation
Epigenetics
Reduce health inequities of Aboriginal Peoples and other vulnerable populations
Pathways to health equity for Aboriginal Peoples
« Back to figure 24
Date modified:
2011-08-02